Stockscreener 앱 받기
3.875
2.88%
-0.115
시간 외 거래:
4.08
0.205
+5.29%
전일 마감가:
$3.99
열려 있는:
$4
하루 거래량:
336.08K
Relative Volume:
0.66
시가총액:
$309.24M
수익:
$16.72M
순이익/손실:
$-77.80M
주가수익비율:
-3.665
EPS:
-1.0573
순현금흐름:
$-43.78M
1주 성능:
-20.43%
1개월 성능:
-41.20%
6개월 성능:
+18.87%
1년 성능:
+217.62%
1일 변동 폭
$3.83
$4.05
1주일 범위
$3.83
$4.91
52주 변동 폭
$1.15
$6.83
Prelude Therapeutics Inc Stock (PRLD) Company Profile
명칭
Prelude Therapeutics Inc
전화
(302) 467-1280
주소
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
3.875 | 318.42M | 16.72M | -77.80M | -43.78M | -1.0573 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 개시 | Jefferies | Buy |
| 2022-03-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-28 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-10-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-26 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2020-11-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-10-20 | 개시 | Goldman | Neutral |
| 2020-10-20 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to S&P Global BMI Index - marketscreener.com
PRLD Initiated Coverage by JP Morgan -- Rating Set to Overweight - GuruFocus
Prelude Therapeutics Initiated at Overweight by JP Morgan - Moomoo
Prelude Therapeutics at H.C. Wainwright conference: pipeline gains momentum By Investing.com - Investing.com Canada
Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial - MyChesCo
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Four executives will join Prelude’s fireside chat Sept. 16 - Stock Titan
Prelude Therapeutics Receives FDA Clearance for New Drug Clinical Trial - Intellectia AI
Prelude Therapeutics (PRLD) Gains FDA Nod for Phase 1 Trial in B - GuruFocus
Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial - marketscreener.com
Prelude gets FDA clearance for breast cancer drug trial - Investing.com
Prelude Therapeutics receives FDA clearance for PRT13722 IND application - TipRanks
Prelude gets FDA clearance for breast cancer drug trial By Investing.com - Investing.com India
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader - Yahoo Finance
Neuraptive Therapeutics, Inc. Announces Key Org… | UNI India - uniindia.com
Prelude Therapeutics (NASDAQ:PRLD) Reaches New 1-Year HighStill a Buy? - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 9.3%Time to Buy? - MarketBeat
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Prelude Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Prelude Therapeutics Hits New 52-Week High of $5.91, Reflecting Strong Growth - MarketsMojo
Prelude Therapeutics Incorporated reports results for the quarter ended June 30Earnings Summary - TradingView
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
We're Not Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn - Moomoo
Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear - webull.com
Prelude Therapeutics (NASDAQ:PRLD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Prelude Therapeutics Reports Q2 2026 Earnings Featuring First Revenue and Reduced Losses - Kalkine Media
Prelude Therapeutics Reports $13.9 Million Q2 Net Loss - Quiver Quantitative
Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash - TradingView
Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TipRanks
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows - TradingView
Prelude Therapeutics 2Q Loss/Shr 14c >PRLD - Moomoo
Prelude Therapeutics Reports $13.9 Million Q2 Net Loss | PRLD Stock News - Quiver Quantitative
Prelude Therapeutics (PRLD) Expected to Post Earnings on Thursday - MarketBeat
Pathos AI pads pipeline with $2.2B Alphamab deal, AZ pact - Fierce Biotech
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High? - Yahoo Finance
PRLD Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock RallyInvestor Earnings Call - vinanet.vn
Prelude Therapeutics (NASDAQ:PRLD) Earns Buy Rating from HC Wainwright - MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Highe - Benzinga
PRLD|Prelude Therapeutics Inc|Price:4.640| - TradingKey
Prelude Therapeutics Inc (PRLD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PRLD|Prelude Therapeutics Inc|Price:3.830|Chg%:-0.100 - TradingKey
Prelude Therapeutics Inc (PRLD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prelude Therapeutics (NASDAQ:PRLD) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Prelude Therapeutics Incorporated Revenue Breakdown – NASDAQ:PRLD - TradingView
Prelude Therapeutics Inc (PRLD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Prelude Therapeutics stock trades around recent lows as clinical pipeline spending weighs on results - Ad-hoc-news.de
PRLD Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesGross Profit Margin - vinanet.vn
Enterprise value to EBITDA forward of Prelude Therapeutics Incorporated – NASDAQ:PRLD - TradingView
Enterprise value to revenue forward of Prelude Therapeutics Incorporated – NASDAQ:PRLD - TradingView
Prelude Therapeutics Inc (PRLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):